Torren Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Torren Management’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-63	Closed	-$1K	–	1033
2025 Q4	$1K	Buy	+63	New	+$893	﹤0.01%	1192

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Torren Management's AUPH Position: Q1 2026 in Review

Torren Management sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2026, closing a stake of 63 shares — an estimated $1K sold.

Torren Management first reported a position in AUPH in Q4 2025 and held it in 1 quarter. The position peaked at $1K in Q4 2025. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

Torren Management reported no remaining Aurinia Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Torren Management sold 63 Aurinia Pharmaceuticals shares in Q1 2026, an estimated $1K.
Torren Management first reported a position in Aurinia Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Torren Management's Aurinia Pharmaceuticals position peaked at $1K in Q4 2025.
259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on Torren Management's 13F filing for Q1 2026, filed 30 Apr 2026.